Understanding economic evidence for the prevention and treatment of atopic eczema

Sach, Tracey ORCID: https://orcid.org/0000-0002-8098-9220, Mcmanus, Emma ORCID: https://orcid.org/0000-0002-3442-8721 and Levell, Nicholas ORCID: https://orcid.org/0000-0003-3393-8305 (2019) Understanding economic evidence for the prevention and treatment of atopic eczema. British Journal of Dermatology, 181 (4). pp. 707-716. ISSN 0007-0963

Preview	PDF (Understanding economic evidence for the prevention and treatment of atopic eczema) - Draft Version Available under License Creative Commons Attribution No Derivatives. Download (635kB) | Preview
Preview	PDF (Accepted_Manuscript) - Accepted Version Download (939kB) | Preview
Preview	PDF (Published_Manuscript) - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (262kB) | Preview

Abstract

Background: Atopic eczema is an inflammatory skin condition, with a similar impact on health-related quality-of-life as other chronic diseases. Increasing pressures on resources within the NHS increase the importance of having good economic evidence to inform their allocation. This paper aims to educate dermatologists about economic methods with illustration to currently available economic evidence on eczema. Methods/design: The type and role of different types of economic evidence is illustrated by evidence found in a systematic literature search conducted across 12 online databases published until 22nd May 2017. Primary empirical studies either reporting the results of a cost of illness study or evaluating the cost, utility or full economic evaluation of interventions for preventing or treating eczema were included. Two reviewers independently assessed studies for eligibility and performed data abstraction, with disagreements resolved by a third reviewer. Evidence tables of results were produced for narrative discussion. The reporting quality of economic evaluations was assessed. Results: 78 studies (described in 80 papers) were deemed eligible. 33 (42%) were judged to be economic evaluations, 12 (15%) cost analyses, 6 (8%) utility analyses, 26 (34%) cost-of-illness studies and 1 feasibility study (1%). The calcineurin inhibitors: tacrolimus and pimecrolimus, as well as barrier creams had most economic evidence available. Partially hydrolysed infant formula was the most commonly evaluated prevention. Conclusions: The current level of economic evidence for interventions aimed at preventing and treating eczema is limited compared to that available for clinical outcomes suggesting that greater collaboration between clinicians and economists might be beneficial.

Item Type:	Article
Uncontrolled Keywords:	economics,costs,cost effectiveness,health related quality of life,atopic eczema
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User:	LivePure Connector
Date Deposited:	11 Feb 2019 17:30
Last Modified:	29 Mar 2024 02:44
URI:	https://ueaeprints.uea.ac.uk/id/eprint/69906
DOI:	10.1111/bjd.17696

Downloads

Actions (login required)

View Item